Kornimate/medical-research-clean huggingface dataset:
human amniotic epithelial stem cell in treatment of refractory severe intrauterine adhesion

Conditions: Intrauterine Adhesion

Summary: this project will investigate the safety and effectiveness of human amniotic epithelial stem cells for treatment of severe refractory asherman's syndrome.

asherman's syndrome is an gynecological disorder caused by the destruction of the endometrium due to repeated or aggressive curettages and/or endometritis. as a result, there is a loss of functional endometrium in multiple areas and the uterine cavity is obliterated by intrauterine adhesions, which results in amenorrhea, hypomenorrhea, infertility and recurrent pregnancy loss. transcervical resection of adhesion (tcra) is the main treatment for asherman's syndrome; so far the effect is usually poor in moderate to severe refractory cases. human amniotic epithelial stem cells (haescs) are derived from human amniotic epithelium. haescs retain the characteristics approximating to embryonic stem cells. animal experiments have shown that the endometrial thickness and fertility of mice was significantly improved after intrauterine therapy with haescs. to further explore the role of haescs in asherman's syndrome patients, this project will evaluate the safety of haescs and find an effective treatment protocols.

Eligibility criteria:
inclusion criteria: * 1. previously diagnosed as uterine adhesion, after the operation of tcra and the postoperatively standardized hormonal replacement therapy(hrt) , recently diagnosed with refractory asherman's syndrome or endometrial atrophy(ea); * 2. according to the american fertility society(afs) classification in 1988, patients are diagnosed of as or ea stageⅲ-ⅳ confirmed by hysteroscopy; * 3. elimination of infertility, recurrent spontaneous abortion or hypomenorrhea caused by other diseases; * 4. be willing to maintain an hrt cycle medication throughout the study, unless it is not tolerated; * 5. normal blood coagulation, liver, heart, and kidney function, absence of hiv, hepatitis b or c, syphilis and psychiatric pathology; * 6. be willing to complete the study and sign the consent form. exclusion criteria: * 1. patients with severe internal disease; * 2. the patients are suffering from gynecologic inflammation or active genital tubercle bacillus; * 3. the patient has other uterine diseases or the abnormal uterine cavity which can't be restored by surgery; * 4. infertility due to a man's cause; * 5. the patient has a previous history of cancer and is undergoing radiotherapy or chemotherapy; * 6. hiv positive * 7. active hepatitis b or c infection, syphilis seropositive * 8. laboratory routine check index abnormality, such as hb（hemoglobin）\ uln（upper limit of normal），alt（glutamic pyruvic transaminase）\>uln and so on; * 9. patients have any complications that may interfere with safety or efficacy or predict life expectancy of less than 24 months; * 10. mental illness in the past 6 months; * 11. patients have a history of drug or alcohol abuse or dependence in the past two years; * 12. unable or unwilling to give informed consent.
single-level and two-level serratus posterior superior intercostal plan block (spsipb)

Conditions: Opioid Consumption; Demographic Data

Summary: breast cancer is the most common malignancy in women; one of the mainstays of breast cancer treatment is surgery, and modified radical mastectomy is one of the standard treatments. postoperative pain can seriously reduce the quality of life in patients, and acute pain can even trigger chronic pain syndrome. thoracic paravertebral, thoracic epidural, intercostal nerve, and interscalene brachial plexus blocks have been used for anesthesia and abrigation during modified radical mastectomy, but their applications are limited due to the complex nature of the procedures and serious complications. in recent years, regional nerve blocks, including intercostal nerve block, erector spinae plane block (espb), and paravertebral block, pecs i-ii block, serratus anterior plane block (sapb), and serratus posterior superior intercostal plane block (spsipb), have been applied for the treatment of postmastectomy pain in breast cancer patients. spsipb has been frequently used for the treatment of acute pain in the postoperative period following surgeries in the thoracic region. spsipb is placed on the spine of the scapula in the sagittal plane to identify the second and third ribs under usg guidance. after visualizing the trapezius and serratus posterior superior (sps) by moving medially to the upper medial border of the scapula, a block is applied to the depths of the sps from above the 3rd rib. the applied local anesthetic solution spreads under the sps muscle. ipsilateral postoperative analgesia is provided with spsipb. spsipb can be applied on the 3rd rib in one go, or on the 3rd and 4th ribs in two go. thus, the local anesthetic solution can be distributed more effectively and more effective postoperative analgesia can be provided.


Eligibility criteria:
inclusion criteria: 1-those between the ages of 18-80 2.those with asa score i-ii-iii 3.those with body mass index (bmi) between 18-40 4.patients who underwent single-level or two-level spsipb together with mastectomy in the operating room exclusion criteria: 1. those under 18 and over 80 2. those with asa score iv and above 3. those with advanced co-morbidities 4. those with a history of bleeding diathesis 5. patients with infection in the area where the block will be performed 6. those with bmi under 18 and over 40 7. patients who underwent surgery under emergency conditions

Keywords: serratus posterior superior intercostal plane block pain breast cancer mastectomy
safety and pharmacokinetics study of e2007 to treat partial and generalised seizures in people with epilepsy

Conditions: Epilepsy

Summary: the objectives of this study were to assess the tolerability and safety of e2007 in patients with refractory partial or generalised seizures and to assess the pharmacokinetics of e2007 in epileptic patients receiving at least one concomitant anti-epileptic drug.


Eligibility criteria:
inclusion criteria a patient who met the following inclusion criteria was eligible to participate in the study: 1. males or females with simple or complex partial seizures with or without secondary generalization, or primary generalized tonic-clonic seizures according to the international league against epilepsy classification. patient records were to document the frequency of seizure. 2. age: 18 to 65 years. 3. race: any. 4. patients receiving up to two additional anti-epileptic medications at doses that were stable for at least the four weeks immediately preceding baseline. 5. patients willing and able to co-operate with the study procedures including completion of patient diaries. 6. patients living at home with a partner or carer able to monitor compliance. 7. patients giving informed consent to participate in the study. exclusion criteria a patient who met the following exclusion criteria was not eligible to participate in the study: 1. pregnant or lactating women. 2. women of childbearing potential unless (1) surgically sterile or (2) practicing effective contraception (eg, abstinence, iud or barrier method plus hormonal method) and having a negative serum beta-hcg result at screening and being willing to remain on the current form of contraception for the duration of the study. postmenopausal women could be included but were to have been amenorrhoeic for at least 12 months to be considered as not being of child-bearing potential. 3. fertile men not willing to use reliable contraception or with partners not willing to use reliable contraception. 4. patients with status epilepticus within the past 24 months. 5. patients with unstable abnormalities of the hepatic, renal, cardiovascular, respiratory, abdominal, haematological, endocrine or metabolic systems which might complicate assessment of the tolerability of the study medication. 6. patients with significantly elevated liver enzymes (abnormal bilirubin level, or serum transaminase levels more than 1.5 times the upper limit of normal). 7. patients taking drugs other than anti-epileptic agents which induce the enzyme cytochrome p450 3a4 (since these might reduce the plasma concentration of e2007), including dexamethasone, rifabutin, rifampacin, st john's wort. 8. patients with past or present drug or alcohol abuse. 9. patients with unstable psychiatric illness. 10. patients who had received an investigational drug within the three months before baseline. 11. patients without a reliable partner or carer. 12. patients with any condition which would make the patient, in the opinion of the investigator, unsuitable for the study.

Keywords: epilepsy e2007 partial seizures generalized seizures
evaluation of the frequency of occurrence of joint pain with bevacizumab in patients with ovarian, colorectal or bronchopulmonary cancer

Conditions: Arthralgia

Summary: self-administered questionnaire survey to determine the presence or absence of joint pain during bevacizumab treatment for lung, ovarian, colorectal cancers. the principal end-point is the frequency of arthralgia after 6 months of treatment with bevacizumab.


Eligibility criteria:
inclusion criteria: * patient with ovarian, colorectal or lung cancer receiving bevacizumab therapy * male or female (aged ≥18 years old) * performance status (ps) between 0 and 2 * expected life\> 3 months * ability to answer a self-questionnaire * obtaining the non-opposition of patient participation exclusion criteria: * pregnant or lactating woman * rapid evolution of neoplastic pathology * major cognitive disorders that do not allow filling of the self-questionnaire * impossibility to submit to medical monitoring for social, psychological or geographical reasons * patients under guardianship or curatorship

Keywords: bevacizumab
progestin priming ovarian stimulation (ppos) compared with antagonist protocol for freeze-all cycles

Conditions: Infertility

Summary: stimulation protocols for ivf underwent several cycles of upgrading aiming to achieve reasonable outcomes with low-cost cycles. antagonist protocols have been introduced as effective and comparable to long agonist regarding the outcomes. however, these protocols are still costly. alternative protocols using progestin suppressions appear options for consideration.


Eligibility criteria:
inclusion criteria: 1. women age of ≥ 18 to ≤ 40; 2. bmi of ≤ 31; 3. all indication for freeze-all 4. pcos; 5. women who have ≥ 1 year of primary or secondary infertility; 6. tubal factor (unilateral, bilateral obstruction or salpingectomy); 7. fresh ejaculate sperm of any count provided they have ≥ 1% normal forms and a motile fraction; 8. women undergoing their first icsi cycle or following a previous successful attempt; 9. women undergoing only frozen-thawed embryo transfer; 10. women with \> 8 mm endometrial thickness at the day of progesterone supplementation in the transfer cycle; 11. women with no detected uterine abnormality on transvaginal ultrasound (e.g. submucosal myomas, polyps or septa). exclusion criteria: 1. unilateral oophorectomy; 2. uterine pathology or abnormality; 3. abnormal karyotyping for them or their male partners; 4. history of repeated abortions or implantation failure; 5. uncontrolled diabetes; 6. liver or renal disease; 7. history of malignancy or borderline pathology; 8. endometriosis; 9. plan for pgd-a; 10. severe male factor includes surgical sperm retrieval or cryopreserved sperm.
neurostimulation for cognitive rehabilitation in stroke

Conditions: Stroke; Cognitive Impairment; Cerebral Infarction

Summary: transcranial direct current stimulation has shown promising results in stroke patients. this study is a double blind, sham-controlled clinical trial aiming to compare the long-term effects of stimulation in two different cognitive regions after a stroke. sixty patients who suffer from chronic strokes will be randomized into 1 of 3 groups: dorsolateral prefrontal cortex, cingulo-opercular network and motor primary cortex (control). each group will receive transcranial direct current stimulation for 20 minutes for 10 consecutive working days (2 weeks). patients will be assessed with a dysexecutive questionnaire, semantic fluency test, categorical verbal fluency and go-no go tests, wechsler adult intelligence scale, rey auditory-verbal learning test, letter comparison and pattern comparison tasks at baseline, after their tenth stimulation session (week 2) and endpoint (week 4). those who achieve clinical improvement with neurostimulation will be invited to receive treatment for 12 months as part of a follow-up study.


Eligibility criteria:
inclusion criteria: * ischaemic chronic stroke * mild/moderate cognitive impairment * informed consent exclusion criteria: * national institute of health stroke scale (nihss) ≥ 16 points * severe cognitive comorbidities (dementia, depression) * transcranial direct current stimulation criteria: use of modulators of the central nervous system drugs; patients with implanted metallic or electronic devices; pacemaker; seizures; pregnancy;any other condition that might limit or interfere in the sensorimotor system
treatment protocol of children with philadelphia chromosome negative high risk acute lymphoblastic leukemia

Conditions: Childhood Acute Lymphoblastic Leukemia; Philadelphia Chromosome, Ph^1^, Absent; B-cell Childhood Acute Lymphoblastic Leukemia

Summary: the cure rate for childhood acute lymphoblastic leukemia (all) has increased significantly in recent decades and expected cure rates now exceed 85%. in recent years, tyrosine kinase inhibitor(tki) has improved outcome of philadelphia chromosome positive (ph+)all . but in some high risk groups, the prognosis of patients is still very bad and the relapse rate is high. clearly, new therapies are urgently needed to prevent and /or treat relapsed all.

1. the prognosis of childhood acute lymphoblastic leukemia(all) has been increased. 2. tyrosine kinase inhibitor(tki) has improved philadelphia chromosome positive (ph+)all treatment outcome. 3. the prognosis of high-risk childhood all except for philadelphia chromosome positive (ph+)all is very bad.

Eligibility criteria:
inclusion criteria: children with high-risk all children lower than 18years old exclusion criteria: bcr/abl(+) children with middle-risk or standard-risk all

Keywords: high risk philadelphia chromosome absent childhood acute lymphoblastic leukemia
optimal treatment frequency of 308-nm excimer laser for vitiligo on the face and neck

Conditions: Vitiligo

Summary: to determine the optimal treatment frequency of 308-nm excimer laser for vitiligo and identify the key clinical variable(s) associated with the treatment efficiency under the optimal treatment frequency. prospective, randomized, comparative study among groups of vitiligo patients treated with 308-nm excimer laser, with the limitation of no follow-up.

vitiligo patients were treated with 308-nm excimer laser for 20 sessions at different frequencies (0.5×, 1.0×, 2.0× and 3.0× weekly). treatment protocols adapted the dose to the lesions and not to the minimal erythemal dose. treatment efficacy was blindly evaluated by 2 independent physicians. re-pigmentation rate was graded on a 6-point scale. the onset of re-pigmentation of vitiligo lesions was evaluated after 5 treatment sessions. the differences between group 0.5×, 1.0×, 2.0× and 3.0× linking different clinical variables were assessed.

Eligibility criteria:
inclusion criteria: * older than 2 years, stable vitiliginous patches during the past 3 months with surfaces of at least 4cm2, and an understanding of all information given by signing a written consent form. exclusion criteria: * pregnant or breastfeeding women; personal history of a hypertrophic scar, skin cancer; taking immunosuppressive or photosensitizing drugs and undergoing phototherapy during the past 3 months.

Keywords: 308-nm excimer laser vitiligo
compare ppv with and without silicone oil in managing postoperative endophthalmitis

Conditions: Endophthalmitis Following Cataract Surgery

Summary: comparing ppv with and without silicone oil in managing postoperative endophthalmitis

the objective of this study is to compare the outcomes of ppv with silicone oil tamponade to ppv alone in patients with postoperative endophthalmitis by assessing visual acuity, and postoperative complications such as rhegmatogenous retinal detachment (rrd).

Eligibility criteria:
inclusion criteria: * adult patients (≥ 18 years) presenting with clinical manifestations of endophthalmitis after cataract surgery exclusion criteria: * patients with concurrent ocular or systemic conditions that could potentially confound study outcomes, such as active retinal diseases unrelated to endophthalmitis * pre-existing poor visual prognosis due to conditions like advanced glaucoma or macular degeneration, or prior ocular surgery affecting the study

Keywords: postoperative endophthalmitis pars plana vitrectomy silicone oil
the effect of opcsp on adherence and clinical outcomes among patients with rheumatic diseases

Conditions: Rheumatic Diseases

Summary: this is a randomised trial on the efficacy of an outpatient pharmacy clinical services program (opcsp) on adherence and clinical outcomes among patients with rheumatic diseases.the purpose of this study is to evaluate: 1. rates of medication adherence in the opcsp program compared with usual care in an integrated health care system. 2. total direct costs and clinical outcomes in the opcsp program compared with usual care in an integrated health care system.

this is a randomised trial on the efficacy of an outpatient pharmacy clinical services program (opcsp) on adherence and clinical outcomes among patients with rheumatic diseases.three types of rheumatic diseases were included in the study, systemic lupus erythematosus (sle), ankylosing spondylitis (as), and rheumatoid arthritis(ra). the purpose of this study is to evaluate: 1. rates of medication adherence in the opcsp program compared with usual care in an integrated health care system. 2. total direct costs and clinical outcomes in the opcsp program compared with usual care in an integrated health care system.

Eligibility criteria:
inclusion criteria: * willingness of the subject to participate in the study, proven by signing the informed consent; * systemic lupus erythematosus (sle), as defined by meeting at least 4 of 11 classification criteria of american college of rheumatology for the classification of systemic lupus erythematosus, either sequentially or coincidentally. the 4 criteria doesn't need to be present at the time of study enrollment; * patients fulfilled the american college of rheumatology criteria for ra and as; exclusion criteria: * patients who are unwilling to sign the inform consent; * pregnancy or lactation

Keywords: pharmaceutical care medication adherence direct costs
clinical evaluation of efficacy of slt to topical medication in lowering iop

Conditions: Glaucoma

Summary: the purpose of this study is to compare selective laser trabeculoplasty (slt) and topical medications for initial treatment of open-angle glaucoma /ocular hypertension based on intraocular pressure reduction, treatment side effects, quality of life measures and costs in south indian population.

selective laser trabeculoplasty (slt), a lasering procedure, is equal to or better than using medication for lowering eye pressure,leading to a better quality of life and being less costly.

Eligibility criteria:
inclusion criteria: diagnosis: poag, pxf glaucoma, pigmentary glaucoma or mixed mechanism poag with a narrow angle, (if laser pi \> 3 months ago) defined by standard examination criteria adequate visualization of angle structures (i.e. clear media and cooperative patient) on no glaucoma medications ou \> 1 month on no systemic medications known to iop (steroids) visual acuity \> 6/24 ou age - more than 35 yrs and less than 72 yrs exclusion criteria: a cumulative lifetime use of eye drops for glaucoma that exceeded 14 days; used any eye drops for glaucoma in the 3 weeks before baseline i visit (washout from \< 14 days of use will be permitted); cigts visual field score that exceeds 16 in either eye; evidence of ocular disease other than glaucoma that might affect the measurements of iop, assessment of visual function, visual field testing proliferative diabetic retinopathy previous intraocular surgery one or both eyes except laser pi more than 3 months ago and cataract extraction with pc iol more than 4 months ago. undergone ophthalmic laser (other than laser pi \> 3 months ago), refractive, conjunctival, or intraocular surgery in either eye; would likely require cataract surgery within 6 months of randomization current or expected use of corticosteroids

Keywords: open angle glaucoma or ocular hypertension
food supplement for the treatment of patients with amyotrophic lateral sclerosis

Conditions: Amyotrophic Lateral Sclerosis

Summary: the purpose of the study is to evaluate the safety of combining phospholipids with medicinal plants for treatment of patients with amyotrophic lateral sclerosis (als)

this is an open label pilot study, where patients (n=10) with als will take a daily nutritional supplement for 8 months. after documenting the als symptom history at baseline, the disease severity, and the motor muscles functions will be assessed at baseline and every two months (0, 2 , 4, 6, 8 months of the treatment). adverse events and side effect will be assessed on every visit and throughout the experiment. in addition, the level of renal function, liver function and electrolytes will be evaluated from blood samples taken at baseline, 4, and 8 months visits.

Eligibility criteria:
inclusion criteria: 1. males aged 18 to 75 years, females\>50 years 2. diagnosis of "probable" or "definite" als according to the el escorial revised criteria 3. a documented history of als symptoms for more than 6 month prior to study enrolment, and no more than 40 month. 4. patients capable of understanding and signing informed consent. exclusion criteria: 1. patients allergic to seafood 2. patients with forced vital capacity \< 75% 3. patients who are respiratory dependent, underwent tracheostomy, or cannot swallow. 4. patients with cardiovascular diseases 5. patients with diabetes 6. patients with active peptic ulcers 7. diagnosis of other neurodegenerative diseases (parkinson disease, alzheimer disease, etc). 8. patients suffering from other chronic significant disease, malignant diseases or any other disease that may risk the patient or interfere with the ability to interpret the results. 9. patients that can not sign/understand the informed consent form. 10. female patients who are pregnant or lactating 11. patients who have received and experimental drug or have participated in a clinical trial within 1 month prior to screening